Erlotinib

Tarceva® is a film-coated tablet contains erlotinib.

Erlotinib is an epidermal growth factor receptor (EGFR also known as HER1) tyrosine kinase inhibitor. Erlotinib potently inhibits the intracellular phosphorylation of EGFR. EGFR is expressed on the cell surface of normal cells and cancer cells.

Therapeutic indications:

Non Small Cell Lung Cancer (NSCLC)

• Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with EGFR activating mutations.
• Tarceva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with EGFR activating mutations and stable disease after first-line
  chemotherapy.
• Tarceva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung
  cancer after failure of at least one prior chemotherapy regimen.

Pancreatic cancer

• Tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.